Senior Project Manager DD&T

Zealand Pharma A/S; Denmark; Hybrid; DKK 900,000 - 1,300,000; Full time

Job summary

Zealand Pharma A/S is seeking a Senior Project Manager to lead complex digital initiatives across the organization. You will partner with the Business Partnership & Delivery team to translate business needs into digital projects, employing structured delivery for major builds and agile methods for ongoing development and data & AI initiatives.

Join a hybrid delivery model aligned with Zealand's Metabolic Frontier 2030 ambitions, collaborating with stakeholders and suppliers to ensure validated,

Qualifications

• Significant experience leading complex digital solutions across the value chain.
• Experience delivering and managing digital initiatives in the life science industry.
• PM certification and agile methodologies preferred.
• Excellent stakeholder management skills.
• Proven ability to plan and run workshops and translate between business needs and technical perspectives.

Responsibilities

• Lead and implement complex initiatives across the organization, both GxP-regulated and non-GxP.
• Design and facilitate solutions in close collaboration with Line of Business.
• Co-develop project timelines, milestones and delivery approach with business and suppliers, choosing structured or agile methods to fit the initiative.
• Track actions, decisions and risks, feeding into a single, consolidated view of the DD&T project portfolio.
• Secure delivery of validated, tested and compliant systems in collaboration with users and stakeholders.
• Facilitate change management and keep all stakeholders informed throughout the projects.

Skills

Experience managing digital solutions

Life science industry experience

Stakeholder management

Workshop facilitation

Bridging business and technical needs

Education

Bachelor/Master in IT or related

PM certification / Agile certification

Job description

Your new position

As a Senior Project Manager, you will lead complex projects and digital initiatives across Zealand Pharma. The role is anchored in Business Partnership & Delivery and works as a strategic counterpart to the business where you will translate business needs into digital projects. You will run a hybrid delivery model, using structured project delivery for large builds and agile ways of working for continuous development and data & AI initiatives. Your work will support Zealand's Metabolic Frontier 2030 ambition.

Responsibilities

• Lead and implement complex initiatives across the organization, both GxP-regulated and non-GxP
• Design and facilitate solutions in close collaboration with Line of Business
• Co-develop project timelines, milestones and delivery approach with business and suppliers, choosing structured or agile methods to fit the initiative
• Track actions, decisions and risks, feeding into a single, consolidated view of the DD&T project portfolio
• Secure delivery of validated, tested and compliant systems in close collaboration with users, System Owners, Process Owners and suppliers
• Facilitate change management and keep all stakeholders informed throughout the projects

Your profile

• Significant experience managing complex digital solutions across the value chain
• Experience delivering and managing digital initiatives in the life science industry
• Certification in project management and agile methodologies is preferred
• Excellent stakeholder management skills
• Proven ability to plan and run workshops and processes, and to translate between Zealand business needs and technical or supplier perspectives
• Business, Bachelor or Master degree within IT and proficiency in English, both verbally and in writing

Your new team

You will join Business Partnership & Delivery, part of Digital, Data & Technology (DD&T) at Zealand Pharma. The team acts as a dedicated strategic partner to the business units across the value chain and owns the health, coherence and governance of the DD&T project portfolio.

Let's bond and be bold

We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.

For further information, please contact Christine Ingemann Kobbel, Head of Business Partnership & Delivery, on [phone].

We are committed to an inclusive recruitment process and welcome applications from all job applicants.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.